“SUBMUCOSAL FIBROSIS AS A BARRIER TO TUMOR EXTENSION: ANATOMICAL AND HISTOLOGICAL INTERPRETATION”
Main Article Content
Keywords
Oral submucous fibrosis, oral squamous cell carcinoma, lymphatic metastasis, extranodal extension, tumor barrier, neck dissection.
Abstract
Background: Oral submucous fibrosis (OSF) is a precancerous disorder that is associated with extensive submucosal collagen accretion. Its possible use as a hindrance to the spread of lymphatic tumors in oral squamous cell carcinoma is under-researched.
Objective: To determine submucosal fibrosis as an anatomical and histologic barrier to lymphatic metastasis and extranodal spread of oral squamous cell carcinoma at its advanced stage.
Materials and Methods: It was a 5-year prospective observational study involving 80 oral squamous cell carcinoma patients at stage III-IV, where the buccal mucosa, alveolus, or retromolar trigone showed the bony involvement. There were 50 patients with concomitant submucosal fibrosis (mostly at stage 3) and 30 without. Each of them was resected at the primary level with the modified radical neck dissection (levels I-V). The histopathologic parameters included nodal yield, metastatic involvement, and extranodal extension.
Results: Patients who had submucosal fibrosis had small nodal metastases (only to levels I-II in 40% and none in 60%), and no extranodal extension. Conversely, the extensive multi-level nodal disease (10 -17 positive nodes) in all patients without fibrosis was common, and the extranodal spread was common.
Conclusion: Submucosal fibrosis is a protective barrier that limits lymphatic dissemination and extranodal progression, which may improve the prognosis of OSF-related advanced oral cancers.
References
2- Tang J, Liu J, Zhou Z, Cui X, Tu H, Jia J, Chen B, Dai X, Liu O. Oral submucous fibrosis: pathogenesis and therapeutic approaches. International Journal of Oral Science. 2025 Feb 1;17(1):8.
3- Wang Y, Zhang F, Qian Z, Jiang Y, Wu D, Liu L, Ning X, Mei J, Chen D, Zhang Y. Targeting collagen to optimize cancer immunotherapy. Experimental Hematology & Oncology. 2025 Jul 29;14(1):101.
4- Sharma M, Shetty SS, Alhedyan F, Radhakrishnan R. Interplay of epigenetics and epistasis drives oral submucous fibrosis. Discover Applied Sciences. 2025 Aug 4;7(8):878.
5- Sharma M, Shetty SS, Alhedyan F, Radhakrishnan R. Interplay of epigenetics and epistasis drives oral submucous fibrosis. Discover Applied Sciences. 2025 Aug 4;7(8):878.
6- Khalaf MA, Ayoub F, Staggers KA, El-Haj JW, Jawaid S, Othman MO. Learning curve for endoscopic submucosal dissection (ESD) in the United States: Large, untutored, single-operator experience. Endoscopy International Open. 2024 Jul;12(07):E905-13.
7- Wu J, Guo CG, Zhao Y, Wang J, Liu J, Li P. Hydrogels for preventing post-endoscopic submucosal dissection stenosis in early esophageal cancer: a comprehensive literature review. Therapeutic Advances in Gastroenterology. 2025 Jun;18:17562848251348971.
8- Lahiri J, Bansod S. IMPLANT PLACEMENT IN ORAL SUBMUCOUS FIBROSIS (OSMF) AND TRISMUS PATIENTS WITH RESTRICTED MOUTH OPENING. Egyptian Journal of Oral and Maxillofacial Surgery. 2024 Oct 1;15(4):202-6.
9- Keihanian T, Othman MO. Colorectal endoscopic submucosal dissection: an update on best practice. Clinical and Experimental Gastroenterology. 2021 Aug 3:317-30.
10- Wadhwa V, Patel N, Grover D, Ali FS, Thosani N. Interventional gastroenterology in oncology. CA: A Cancer Journal for Clinicians. 2023 May;73(3):286-319.
11- Macias-Ceja DC, Mendoza-Ballesteros MT, Ortega-Albiach M, Barrachina MD, Ortiz-Masià D. Role of the epithelial barrier in intestinal fibrosis associated with inflammatory bowel disease: relevance of the epithelial-to-mesenchymal transition. Frontiers in Cell and Developmental Biology. 2023 Sep 26;11:1258843.
12- Wang Z, Han Y, Peng Y, Shao S, Nie H, Xia K, Xiong H, Su T. Senescent epithelial cells remodel the microenvironment for the progression of oral submucous fibrosis through secreting TGF-β1. PeerJ. 2023 Apr 19;11:e15158.
13- Gao G, Lin C, Li R, Xie X, Luo HB. Epigallocatechin-3-gallate inhibits the collagen accumulation of oral submucous fibrosis induced by arecoline. Frontiers in Pharmacology. 2025 Jan 31;16:1540559.
14- Murray AM, Swingle KL, Mitchell MJ. Engineering Nanoparticles for Gynecologic Cancer Therapy. ACS nano. 2025 Aug 19;19(34):30758-85.
15- Xu H, Lyu FY, Song JY, Xu YM, Jiang EH, Shang ZJ, Chen LL, Xu Z. Research achievements of oral submucous fibrosis: progress and prospect. BioMed Research International. 2021;2021(1):6631856.
16- Sol Ju P, Dong L, Daotong LI, Chen F, Hu X, Ma C. Microbial Signatures of Areca Nut Chewing: Bridging the Gap between Oral Dysbiosis and Submucous Fibrosis.
17- Chen H, Xu X, Li J, Xue Y, Li X, Zhang K, Jiang H, Liu X, Li M. Decoding tumor-fibrosis interplay: mechanisms, impact on progression, and innovative therapeutic strategies. Frontiers in Pharmacology. 2024 Oct 23;15:1491400.
18- Szekely D, Zara F, Patrascu R, Dumitru CS, Novacescu D, Manole A, Mogoanta CA, Iovanescu D, Iovanescu G. Histopathological and Molecular Insights into Chronic Nasopharyngeal and Otic Disorders in Children: Structural and Immune Mechanisms Underlying Disease Chronicity. Life. 2025 Aug 3;15(8):1228.

